In stockTesamorelin 10 mg
Lyophilized vial 10 mg
GHRH Analog
Out of stockThe Triple Agonist
Presentation
Next-generation triagonist studied for its coordinated action on metabolic pathways and energy balance.
Need help? Contact support.
Next-generation triagonist studied for its coordinated action on metabolic pathways and energy balance.
Sealed vial: 2–8 °C short term; −20 °C for long-term storage. Protect from light and humidity.
Reconstituted vial: 2–8 °C. Indicative stability of 14–28 days depending on the peptide.
Avoid freeze-thaw cycles. Discard if turbidity or precipitate is observed.
Lyophilized vial 10 mg
Available presentations: 10 mg, 20 mg, 30 mg.
Packaged in a sealed vial with rubber septum, labeled with batch and analysis date.
How do I verify the purity of the vial?
Each batch is accompanied by a downloadable COA with ≥99% HPLC purity, ESI-MS identity and a traceable batch number. You can also verify the batch at /verificar-lote.
How long does shipping take in Mexico?
Orders ship the next business day and typically arrive within 24–72 h via national courier. Discreet packaging with cold gel when applicable.
Can I change the presentation?
Yes — if the product has multiple presentations (mg), they appear in the selector above. For sizes outside the catalog, contact us via WhatsApp.
Is this product for human consumption?
No. Products are Research Use Only (RUO), intended exclusively for in vitro scientific research and preclinical models.
Product intended solely for in vitro scientific research. Not fit for human or veterinary consumption.
Retatrutide is a next-generation synthetic peptide classified as a triple agonist of the GLP-1, GIP and glucagon receptors (GLP-1/GIP/GCGR). In the phase 2 trial published in The New England Journal of Medicine (Jastreboff et al., 2023), the 12 mg group showed a mean 24.2% reduction in body weight at 48 weeks — the largest percentage documented to date among incretin agonists. Peptide Life offers it in lyophilized form with ≥99% HPLC purity, exclusively for in vitro scientific research.
Unlike Semaglutide (single GLP-1 agonist) or Tirzepatide (dual GLP-1/GIP), Retatrutide simultaneously activates three metabolic receptors: GLP-1R (satiety and glucose-dependent insulin secretion), GIPR (glycemic homeostasis and adipose signaling), and GCGR (energy expenditure, hepatic glucose production and substrate mobilization). The hypothesis is that coordinated activation of these three pathways yields greater fat-mass reduction than one- or two-receptor agonism.
| Parameter | Value |
|---|---|
| Name | Retatrutide |
| CAS / Sequence | Triple agonist GLP-1/GIP/GCGR |
| Presentation | Lyophilized vial 10 mg |
| Purity | ≥99% HPLC-UV 220 nm |
| Identity | ESI-MS ±0.1 Da |
| Storage | −20°C |
| Shelf life | ≥18 months |
| Use | Research use only (RUO) |
| Price | $2,070 MXN (VAT included) |
In stockLyophilized vial 10 mg
GHRH Analog
In stockLyophilized vial 10 mg
NNMT Inhibitor
Out of stockLyophilized vial 5 mg
GLP-1 Agonist